Express Mail No.: EV452776127US

IN THE CLAIMS:

Listing of Claims:

1-30 (Cancelled).

- 31. (Currently amended) A method of <u>for</u> treatment of <u>the human or animal body</u> a <u>metabolic disorder or condition related to an α -galactosidase A deficiency</u>, said method comprising administering <u>to a subject in need thereof</u> an effective, non-toxic amount of a pharmaceutical composition comprising:
 - (a) an expression cassette operably linked to:
 - (i) a myosin light chain enhancer;
- (ii) a promoter selected from a myosin heavy chain promoter and a viral promoter; and
 - (iii) a polynucleotide sequence encoding a polypeptide of therapeutic use; or
 - (b) a vector comprising said expression cassette; or
- (c) a viral strain comprising said expression cassette combined with a pharmaceutically acceptable carrier or diluent.
- 32. (Previously presented) The method of claim 31, wherein said vector is a plasmid vector or a viral vector.
- 33. (Previously presented) The method of claim 31, wherein said expression cassette is administered as a naked nucleic acid construct.
- 34. (Previously presented) The method of claim 31, wherein said pharmaceutical composition is formulated for intramuscular administration.
- 35. (Previously presented) The method of claim 31, wherein said myosin light chain enhancer is a myosin light chain 1/3 enhancer.
 - 36-39 (Cancelled).
- 40. (Previously presented) The method of claim 31, wherein said viral promoter is a cytomegalovirus promoter or a herpes simplex virus promoter.
- 41. (Currently amended) The method of claim 31, wherein said vector further comprises fish or mammalian genomic sequences flanking said expression cassette.
- 42. (Currently amended) The method of claim 31, wherein said vector further comprises viral genomic sequences flanking said expression cassette.
 - 43-50 (Cancelled).
- 51. (Currently amended) The method of claim 31, wherein said polynucleotide sequence comprises a heterologous gene.
 - 52-57 (Cancelled).

Express Mail No.: EV452776127US

- 58. (Currently amended) A method of <u>for</u> treatment of <u>the human or animal body</u> a metabolic disorder or condition related to an α-galactosidase A deficiency, said method comprising administering to a subject in need thereof an effective, non-toxic amount of a pharmaceutical composition comprising:
 - (a) an expression cassette operably linked to:
 - (i) a myosin light chain enhancer;
- (ii) a promoter selected from a myosin heavy chain promoter and a viral promoter; and
- (iii) a polynucleotide sequence encoding a polypeptide of therapeutic use which is not a blood coagulation factor; or
 - (b) a vector comprising said expression cassette; or
- (c) a viral strain comprising said expression cassette combined with a pharmaceutically acceptable carrier or diluent.
- 59. (Previously presented) The method of claim 58, wherein said vector is a plasmid vector or a viral vector.
- 60. (Previously presented) The method of claim 58, wherein said expression cassette is administered as a naked nucleic acid construct.
- 61. (Previously presented) The method of claim 58, wherein said pharmaceutical composition is formulated for intramuscular administration.
- 62. (Previously presented) The method of claim 58, wherein said myosin light chain enhancer is a myosin light chain 1/3 enhancer.
 - 63-66 (Cancelled).
- 67. (Previously presented) The method of claim 58, wherein said viral promoter is a cytomegalovirus promoter or a herpes simplex virus promoter.
- 68. (Currently amended) The method of claim 58, wherein said vector further comprises fish or mammalian genomic sequences flanking said expression cassette.
- 69. (Currently amended) The method of claim 58, wherein said vector further comprises viral genomic sequences flanking said expression cassette.
 - 70-77 (Cancelled)
- 78. (Currently amended) The method of claim 58, wherein said polynucleotide sequence comprises a heterologous gene.
 - 79-96 (Cancelled).
- 97. (New) The method of claim 31 or 58, wherein the subject in need of treatment is an animal.
 - 98. (New) The method of claim 97, wherein the animal is a human.